3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
29
Urinary Bladder Neoplasms
26
Carcinoma, Renal Cell
22
Carcinoma, Non-Small-Cell Lung
10
Neoplasms
7
Neoplasm Metastasis
7
Squamous Cell Carcinoma of Head and Neck
6
Ureteral Neoplasms
5
Prostatic Neoplasms
5
Ovarian Neoplasms
5
Melanoma
5
Carcinoma, Merkel Cell
5
Urethral Neoplasms
4
Triple Negative Breast Neoplasms
4
Stomach Neoplasms
4
Small Cell Lung Carcinoma
3
Kidney Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Penile Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
2
Lung Neoplasms
2
Kidney Diseases
2
Head and Neck Neoplasms
2
Urothelial Cancer
1
Urologic Neoplasms
1
Turcot syndrome
1
Testicular Neoplasms
1
Interventions
Gemcitabine
9
pembrolizumab
7
Cisplatin
5
enfortumab vedotin
4
atezolizumab
4
Trastuzumab
4
Mitomycin
4
Carboplatin
4
Sunitinib
3
Pemetrexed
3
dodecyl maltoside
2
cabozantinib
2
Water
2
Sugammadex
2
Standard of Care
2
Saline Solution
2
Paclitaxel
2
Nivolumab
2
Neostigmine
2
Docetaxel
2
Cetuximab
2
Bevacizumab
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
vinflunine
1
valrubicin
1
tucatinib
1
tislelizumab
1
testosterone 17 beta-cypionate
1
temsirolimus
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
avelumab
×
Genitourinary
×
Clear all
NCT02603432
2024-03-27
JAVELIN Bladder 100
Pfizer
Phase 3
Completed
700 enrolled
35 charts
1 FDA